Total Funding
$246.6M
Employee Range
101-250
Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.
Symphogen data powered by:
Share
Symphogen data powered by:
SymphogenOverall Ranking
Regional Rank
Share
Loading...
In Western Europe
Top null%out of startups
SymphogenIndustry Rankings in
Healthtech
City Rank
Share
1st
In Lyngby
Top 13%out of 8 startups
National Rank
Share
2nd
In Denmark
Top 2%out of 147 startups
Regional Rank
Share
143rd
In Western Europe
Top 4%out of 4369 startups
SymphogenSubindustry Rankings in
BiotechnologyCity Rank
Share
1st
In Lyngby
Top 25%out of 4 startups
National Rank
Share
1st
In Denmark
Top 2%out of 78 startups
Regional Rank
Share
24th
In Western Europe
Top 2%out of 1765 startups
rankings by:
SymphogenSB Rank Evolution
Not enough data points to display the chart.
SymphogenstartupComparison
National Ranking (undefined)
Loading...
...
Regional Ranking (undefined)
Loading...
...
Global Ranking (WorldWide)
Loading...
...
Industry Ranking (undefined)
Loading...
...
SubIndustry Ranking (undefined)
Loading...
...
See all ranked entities with a premium subscription
Get Pro